Concomitant Tricuspid Valve Surgery Does Not Increase Operative Risk During Robotic Mitral Valve Surgery
Gökhan Arslanhan1, Murat Baştopçu2, Zeynep Sıla özcan1, Sahin Senay1, Muharrem Kocyigit1, Ahmet Umit Gullu1, Ahmet Akyol1, Cem Alhan1.
1Acibadem Mehmet Ali Aydinlar University School of Medicine, ISTANBUL, Turkey, 2Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Research and Training Hospital, ISTANBUL, Turkey.
BACKGROUND: The aim of this study was to investigate the outcomes of robotic mitral valve surgery with and without concomitant tricuspid valve surgery.
METHODS: Patients who underwent robotic mitral surgery between March 2010 and September 2022 were included. Patients were grouped according to the presence of concomitant tricuspid interventions. The groups were compared for baseline factors, operative parameters, and early postoperative outcomes.
RESULTS: The study included 285 robotic mitral surgery patients. 59 patients underwent concomitant tricuspid interventions. In the concomitant tricuspid surgery group, cardiopulmonary bypass time (150.1 vs 128.4 min, p<0.001) and cross clamp time (99.2 vs 82.4 min, p<0.001) were longer. Prolonged intubation was more frequent in the concomitant tricuspid intervention group (5.2% vs 0.5%, p=0.029). The groups did not differ in terms of mortality, permanent pacemaker requirement, or other morbidities. CONCLUSIONS:The robotic approach for mitral disease and coexisting tricuspid disease may offer a safe approach without an increased risk of mortality or morbidity.
Back to 2023 ePosters